BiologicalDrug
Raludotatug deruxtecan clinical trials
Also written DS-6000a and MK-5909.
Keep track of what changes. Save the raludotatug deruxtecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
Ifinatamab deruxtecan (2) · Pembrolizumab/Quavonlimab MK-1308A (1) · Lenvatinib (1) · Anti-ILT4 Monoclonal Antibody MK-4830 (1) · Favezelimab/Pembrolizumab Formulation (1) · Carboplatin (1) · Paclitaxel (1) · Bevacizumab (1)
Studies
Open first, then newest update. How each study uses raludotatug deruxtecan is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06843447Written as Raludotatug Deruxtecan
- A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07776691Written as R-DXd
- A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07743164Written as R-DXd
- Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06780098Written as R-DXD
- A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06780085Written as Raludotatug Deruxtecan
- A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)Not yet recruitingPhase 3Daiichi SankyoNCT07791732Written as R-DXd
- A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerRecruitingPhase 2/3Daiichi SankyoNCT06161025Written as R-DXd
- A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)Active, not recruitingPhase 2Daiichi SankyoNCT06660654Written as Raludotatug deruxtecan
- A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian TumorsActive, not recruitingPhase 1Daiichi SankyoNCT04707248Written as DS-6000a
- Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Active, not recruitingPhase 1/2Merck Sharp & Dohme LLCNCT04938817Written as R-DXd
- A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06864169Written as Raludotatug Deruxtecan (R-DXd)
Codes
What other systems call raludotatug deruxtecan · ClinicalTrials.gg INT016128
- UNII (FDA) BPQ010OFD7RALUDOTATUG DERUXTECANOne source FDA
- NCI Thesaurus C179214Raludotatug DeruxtecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | BPQ010OFD7 | RALUDOTATUG DERUXTECAN | One source FDA |
| NCI Thesaurus | C179214 | Raludotatug Deruxtecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.